Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Indivior Investment Reflects Progress Towards Clinical Evaluation and Validates Power of Allosteric Platform Geneva, Switzerland, October 8, 2019 – Addex Therapeutics (SIX: ADXN), a leading...
-
Geneva, Switzerland, September 30, 2019 – Addex Therapeutics (SIX: ADXN), a leading allosteric modulation-based drug discovery and development company, today reported its half-year financial results...
-
Geneva, Switzerland, September 25, 2019 – Addex Therapeutics (SIX:ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, will discuss its half-year 2019...
-
Geneva, Switzerland, 24 September 2019 -- Addex Therapeutics Ltd (SIX: ADXN) (the Company), a leading company pioneering allosteric modulation-based drug discovery and development, today announced it...
-
Geneva, Switzerland, August 27, 2019 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development today announced that the independent life...
-
Geneva, Switzerland, July 9, 2019 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, today announced that it will lead a...
-
Geneva, Switzerland, 20 June 2019 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that its shareholders...
-
Geneva, Switzerland, May 28, 2019 – Addex Therapeutics (SIX: ADXN) announced today that its Annual General Meeting will take place on Wednesday, June 19, 2019, at 11:00am at the Campus Biotech, Chemin...
-
Geneva, Switzerland, May 20, 2019 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, today announced that it has increased its...
-
Geneva, Switzerland, May 8, 2019 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer will give...